| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation.
|
Br J Haematol
|
2004
|
1.50
|
|
2
|
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome.
|
Acta Haematol
|
2015
|
1.42
|
|
3
|
Outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with monosomal karyotypes.
|
Acta Haematol
|
2014
|
1.39
|
|
4
|
Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
|
Acta Haematol
|
2014
|
1.38
|
|
5
|
Clinical significance of microsatellite instability for stage II or III colorectal cancer following adjuvant therapy with doxifluridine.
|
Med Oncol
|
2010
|
1.38
|
|
6
|
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
|
Blood
|
2006
|
1.36
|
|
7
|
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer.
|
Clin Cancer Res
|
2008
|
1.32
|
|
8
|
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.
|
Haematologica
|
2010
|
1.16
|
|
9
|
Preferences for and experiences of family involvement in cancer treatment decision-making: patient-caregiver dyads study.
|
Psychooncology
|
2013
|
1.15
|
|
10
|
Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry.
|
Int J Hematol
|
2013
|
1.14
|
|
11
|
Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
|
Eur J Haematol
|
2004
|
1.09
|
|
12
|
Prognostic impact of microRNA-related gene polymorphisms on survival of patients with colorectal cancer.
|
J Cancer Res Clin Oncol
|
2010
|
1.09
|
|
13
|
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
|
Leuk Lymphoma
|
2005
|
1.03
|
|
14
|
Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
|
Clin Lymphoma Myeloma
|
2008
|
1.02
|
|
15
|
Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis.
|
J Korean Med Sci
|
2008
|
1.01
|
|
16
|
Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype.
|
J Clin Oncol
|
2011
|
0.98
|
|
17
|
Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
|
Br J Haematol
|
2007
|
0.97
|
|
18
|
New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
|
Biol Blood Marrow Transplant
|
2006
|
0.95
|
|
19
|
Malignant peripheral nerve sheath tumor in neurofibromatosis type I: unusual presentation of intraabdominal or intrathoracic mass.
|
Korean J Intern Med
|
2005
|
0.95
|
|
20
|
Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
|
Ann Hematol
|
2012
|
0.95
|
|
21
|
Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia.
|
Int J Cancer
|
2006
|
0.93
|
|
22
|
Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer.
|
Oncology
|
2007
|
0.93
|
|
23
|
BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.
|
Leuk Res
|
2009
|
0.92
|
|
24
|
No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer.
|
Cancer Res Treat
|
2009
|
0.91
|
|
25
|
Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients.
|
Med Oncol
|
2011
|
0.91
|
|
26
|
IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation.
|
Transplantation
|
2005
|
0.90
|
|
27
|
A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia.
|
Blood
|
2011
|
0.90
|
|
28
|
CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.
|
Cancer Chemother Pharmacol
|
2005
|
0.90
|
|
29
|
Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
|
Oncology
|
2005
|
0.90
|
|
30
|
A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
|
Int J Hematol
|
2006
|
0.89
|
|
31
|
Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer.
|
J Korean Med Sci
|
2008
|
0.89
|
|
32
|
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
|
Ann Hematol
|
2012
|
0.88
|
|
33
|
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
|
Cancer Chemother Pharmacol
|
2007
|
0.88
|
|
34
|
Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.
|
Am J Hematol
|
2011
|
0.88
|
|
35
|
Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2008
|
0.88
|
|
36
|
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
|
Cancer Chemother Pharmacol
|
2009
|
0.88
|
|
37
|
Acute myeloid leukemia presenting as obstructive jaundice caused by granulocytic sarcoma.
|
Gut Liver
|
2007
|
0.88
|
|
38
|
Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
|
Eur J Haematol
|
2005
|
0.87
|
|
39
|
Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation.
|
Transplantation
|
2007
|
0.86
|
|
40
|
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
|
Ann Hematol
|
2011
|
0.86
|
|
41
|
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
|
Ann Hematol
|
2013
|
0.86
|
|
42
|
Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category.
|
Genes Chromosomes Cancer
|
2012
|
0.86
|
|
43
|
Pain and its treatment in patients with cancer in Korea.
|
Oncology
|
2003
|
0.86
|
|
44
|
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
|
Ann Hematol
|
2010
|
0.86
|
|
45
|
RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection.
|
J Cancer Res Clin Oncol
|
2010
|
0.86
|
|
46
|
Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation.
|
Ann Hematol
|
2004
|
0.86
|
|
47
|
Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
|
Oncology
|
2011
|
0.85
|
|
48
|
Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
|
Clin Cancer Res
|
2009
|
0.85
|
|
49
|
Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients.
|
Br J Haematol
|
2007
|
0.85
|
|
50
|
A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
|
Ann Hematol
|
2012
|
0.85
|
|
51
|
Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry.
|
Acta Haematol
|
2009
|
0.85
|
|
52
|
Comparison between matched related and alternative donors of allogeneic hematopoietic stem cells transplanted into adult patients with acquired aplastic anemia: multivariate and propensity score-matched analysis.
|
Biol Blood Marrow Transplant
|
2011
|
0.84
|
|
53
|
c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas.
|
Leuk Lymphoma
|
2006
|
0.84
|
|
54
|
TNF superfamily gene polymorphism as prognostic factor in early breast cancer.
|
J Cancer Res Clin Oncol
|
2009
|
0.84
|
|
55
|
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
|
Transfusion
|
2013
|
0.84
|
|
56
|
Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
|
Ann Hematol
|
2014
|
0.83
|
|
57
|
Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
|
Leuk Lymphoma
|
2012
|
0.83
|
|
58
|
Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
|
Acta Haematol
|
2006
|
0.83
|
|
59
|
Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.
|
Invest New Drugs
|
2011
|
0.82
|
|
60
|
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
|
Cancer Chemother Pharmacol
|
2008
|
0.82
|
|
61
|
Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
0.82
|
|
62
|
Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse.
|
Acta Haematol
|
2010
|
0.81
|
|
63
|
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
|
J Korean Med Sci
|
2009
|
0.81
|
|
64
|
Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
|
Clin Transplant
|
2008
|
0.81
|
|
65
|
Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.
|
Korean J Intern Med
|
2006
|
0.81
|
|
66
|
Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen.
|
Acta Haematol
|
2005
|
0.80
|
|
67
|
Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.
|
Cancer Chemother Pharmacol
|
2009
|
0.79
|
|
68
|
Consideration of aggressive therapeutic strategies for primary testicular lymphoma.
|
Am J Hematol
|
2007
|
0.79
|
|
69
|
The association between multidrug resistance-1 gene polymorphisms and outcomes of allogeneic HLA-identical stem cell transplantation.
|
Haematologica
|
2006
|
0.79
|
|
70
|
Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
|
Ann Hematol
|
2011
|
0.78
|
|
71
|
Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.
|
Int J Hematol
|
2012
|
0.78
|
|
72
|
Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
|
Ann Hematol
|
2010
|
0.78
|
|
73
|
No association of the NFKB1 insertion/deletion promoter polymorphism with survival in patients with gastric cancer.
|
Jpn J Clin Oncol
|
2009
|
0.78
|
|
74
|
[FLT3 Gene Mutations as a Prognostic Factor for Acute Myeloid Leukemia.].
|
Korean J Lab Med
|
2006
|
0.78
|
|
75
|
VARS2 V552V variant as prognostic marker in patients with early breast cancer.
|
Med Oncol
|
2010
|
0.78
|
|
76
|
Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas.
|
Ann Hematol
|
2006
|
0.78
|
|
77
|
Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.
|
Int J Hematol
|
2013
|
0.78
|
|
78
|
Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation.
|
J Clin Apher
|
2009
|
0.78
|
|
79
|
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
|
J Cancer Res Clin Oncol
|
2010
|
0.78
|
|
80
|
Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement.
|
Cancer Res Treat
|
2013
|
0.78
|
|
81
|
High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma.
|
Leuk Lymphoma
|
2005
|
0.78
|
|
82
|
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
|
J Korean Med Sci
|
2009
|
0.78
|
|
83
|
Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype.
|
Br J Haematol
|
2013
|
0.78
|
|
84
|
Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
|
Jpn J Clin Oncol
|
2010
|
0.77
|
|
85
|
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
|
Am J Hematol
|
2012
|
0.77
|
|
86
|
Survival benefit of asymptomatic cytomegalovirus reactivation after HLA-identical allogeneic peripheral blood stem cell transplantation.
|
Transplantation
|
2006
|
0.77
|
|
87
|
Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
|
Leuk Lymphoma
|
2007
|
0.77
|
|
88
|
No Association of Insulin-like Growth Factor Gene Polymorphisms with Survival in Patients with Colorectal Cancer.
|
Cancer Res Treat
|
2011
|
0.77
|
|
89
|
GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization.
|
Cancer Genet Cytogenet
|
2010
|
0.77
|
|
90
|
Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes.
|
Acta Haematol
|
2005
|
0.77
|
|
91
|
Predicting outcomes of HLA-identical allogeneic stem cell transplants from variable number of tandem repeat disparity between donors and recipients.
|
Haematologica
|
2006
|
0.77
|
|
92
|
Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.
|
Korean J Intern Med
|
2012
|
0.77
|
|
93
|
Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
|
Ann Hematol
|
2013
|
0.76
|
|
94
|
Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.
|
J Korean Med Sci
|
2005
|
0.76
|
|
95
|
Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML.
|
Chonnam Med J
|
2011
|
0.76
|
|
96
|
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2007
|
0.76
|
|
97
|
Allogeneic hematopoietic stem cell transplant for adults over 40 years old with acquired aplastic anemia.
|
Biol Blood Marrow Transplant
|
2012
|
0.76
|
|
98
|
Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors.
|
Am J Hematol
|
2008
|
0.76
|
|
99
|
Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia.
|
Leuk Res
|
2013
|
0.75
|
|
100
|
Clinical significance of platelet count at day +60 after allogeneic peripheral blood stem cell transplantation.
|
J Korean Med Sci
|
2006
|
0.75
|
|
101
|
Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
|
J Korean Med Sci
|
2004
|
0.75
|
|
102
|
No association of the hypoxia-inducible factor-1α gene polymorphisms with survival in patients with colorectal cancer.
|
Med Oncol
|
2010
|
0.75
|
|
103
|
Prognostic Impact of Polymorphisms in the CASPASE Genes on Survival of Patients with Colorectal Cancer.
|
Cancer Res Treat
|
2012
|
0.75
|
|
104
|
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
|
Am J Hematol
|
2012
|
0.75
|
|
105
|
Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer.
|
J Korean Med Sci
|
2007
|
0.75
|
|
106
|
Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia.
|
Leuk Lymphoma
|
2006
|
0.75
|
|
107
|
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
|
Int J Hematol
|
2014
|
0.75
|
|
108
|
Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.
|
Leuk Lymphoma
|
2005
|
0.75
|
|
109
|
Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
|
Jpn J Clin Oncol
|
2005
|
0.75
|
|
110
|
No association of the eNOS gene polymorphisms with survival in patients with colorectal cancer.
|
Med Oncol
|
2010
|
0.75
|
|
111
|
Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors.
|
Ann Hematol
|
2010
|
0.75
|